Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

BUY
$18.12 - $27.32 $706,680 - $1.07 Million
39,000 Added 86.67%
84,000 $1.9 Million
Q3 2022

Nov 04, 2022

SELL
$16.98 - $25.54 $254,700 - $383,100
-15,000 Reduced 25.0%
45,000 $844,000
Q2 2022

Aug 05, 2022

BUY
$13.15 - $20.45 $789,000 - $1.23 Million
60,000 New
60,000 $1.12 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Granite Point Capital Management, L.P. Portfolio

Follow Granite Point Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Granite Point Capital Management, L.P. with notifications on news.